Senhwa Biosciencesinc A Clinical Stage Drug Development Company Focused On Next Generation Dna Damage Responseddrtherapeutics For The Treatment Of Cancer Currently 2 Main Compounds Cx 5461 And Cx 4945 Are Both Firstinclass Small Molecule Drugs Andongoing Phase I Ii Clinical Trials In Australiacanadaunited Stateskorea And Taiwansenhwa S Cx 5461 Is A G Quadruplexesg4Stabilizercausing Dna Damage Of Tumor Cells Through A Synthetic Lethalityslapproach In Patients With Brca1 2 Mutations Or Hr Deficiencyhrd Senhwa S Cx 4945 Is A Selective Ck2 Inhibitor And It Has Been Shown To Inhibit The Phosphorylation Of The Dna Repair Protein Xrcc1 And Subsequently Enhance The Activity Of Dna Damaging Chemotherapy Agentssenhwa Has A Strong Management Team With Proven Track Records In Developing New Drugs And Targeted Agentsheadquartered In Taiwanbut With A Vital Operational Base In San Diegocaliforniathe Senhwa Team Is Well Positioned To Oversee The Development Of Their Compounds By Collaborating With A Diverse Range Of Global Investigators And Service Providers
